Japanese companies have been slow to progress COVID-19 vaccines, but today Daiichi Sankyo (TYO: 4568) announced that it has received approval for the manufacturing and marketing of Daichirona for Intramuscular Injection (DS-5670), an original monovalent mRNA vaccine against the novel coronavirus infectious diseasein Japan for the prevention of infectious disease caused by SARS-CoV-2 (booster vaccination).
The application for approval of Daichirona for its manufacturing and marketing in Japan was submitted in January 2023, and it is now approved as the first Japan-made mRNA vaccine against COVID-19. Daichirona can be distributed and stored under refrigeration (2°C–8°C), offering improved convenience to healthcare professionals.
Daiichi Sankyo notes that, in the current special temporary vaccination program against COVID-19, Omicron-adapted bivalent mRNA vaccines are used for the booster series campaign that began in May 2023. In addition, the Japanese government has shown an intention to use XBB.1 vaccines for the next booster series campaign that is scheduled to begin in September 2023. Since Daichirona as approved now is an original monovalent mRNA vaccine for booster series, its supply for the campaign is not planned.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze